Month 24 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial

IMPORTANCE: Two-year outcomes are reported comparing eyes originally assigned to aflibercept or bevacizumab to assess the need for continued anti–vascular endothelial growth factor (VEGF) therapy for macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Ophthalmol
Main Authors: Scott, Ingrid U., Oden, Neal L., VanVeldhuisen, Paul C., Ip, Michael S., Blodi, Barbara A., Chan, Clement K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6802250/
https://ncbi.nlm.nih.gov/pubmed/31600368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2019.3947
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados